AbbVie (NYSE:ABBV) Stock Price Down 3.8% - Time to Sell?

Key Points

• Shares fell 3.8%, trading as low as $217.86 and last at $220.57 on Monday, with volume rising about 45% to roughly 8.87 million shares versus the average.
• Analysts rate AbbVie a "Moderate Buy" with an average target of $245.84, and several firms have recently raised ratings/targets (e.g., HSBC to Strong Buy, Wells Fargo to Overweight).
• AbbVie raised its quarterly dividend to $1.73 (annualized $6.92) for a ~3.1% yield, though the reported payout ratio is unusually high at 524%, despite a recent quarterly earnings beat and guidance for Q4 2025 EPS of 3.320–3.360.

AbbVie Inc. (NYSE:ABBV - Get Free Report)'s share price dropped 3.8% on Monday . The stock traded as low as $217.86 and last traded at $220.5710. Approximately 8,868,660 shares were traded during mid-day trading, an increase of 45% from the average daily volume of 6,101,917 shares. The stock had previously closed at $229.31.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ABBV. Hsbc Global Res upgraded AbbVie from a "hold" rating to a "strong-buy" rating in a report on Wednesday, December 10th. Bank of America upped their target price on shares of AbbVie from $220.00 to $251.00 and gave the stock a "neutral" rating in a research report on Friday, October 3rd. Wells Fargo & Company upped their price target on shares of AbbVie from $240.00 to $260.00 and gave the stock an "overweight" rating in a research note on Friday, September 12th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of AbbVie in a report on Wednesday, October 8th. Finally, Scotiabank started coverage on shares of AbbVie in a research report on Thursday, November 13th. They set a "sector outperform" rating and a $280.00 price objective on the stock. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, AbbVie currently has an average rating of "Moderate Buy" and an average target price of $245.84.

AbbVie Stock Down 3.8%

The company's 50-day simple moving average is $226.54 and its 200 day simple moving average is $214.39. The stock has a market capitalization of $389.83 billion, a price-to-earnings ratio of 167.10, a P/E/G ratio of 0.96 and a beta of 0.36.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analysts' expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. AbbVie's revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the company earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie's previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. AbbVie's payout ratio is currently 524.24%.

Institutional Trading of AbbVie

Hedge funds have recently made changes to their positions in the company. Coastline Trust Co increased its position in AbbVie by 27.0% in the 4th quarter. Coastline Trust Co now owns 49,354 shares of the company's stock valued at $11,277,000 after buying an additional 10,492 shares in the last quarter. Holos Integrated Wealth LLC bought a new position in shares of AbbVie in the fourth quarter valued at approximately $207,000. Legacy Wealth Management LLC MS increased its holdings in AbbVie by 7.7% during the fourth quarter. Legacy Wealth Management LLC MS now owns 952 shares of the company's stock worth $218,000 after buying an additional 68 shares during the last quarter. Grant Private Wealth Management Inc lifted its stake in AbbVie by 10.3% in the fourth quarter. Grant Private Wealth Management Inc now owns 3,215 shares of the company's stock valued at $735,000 after purchasing an additional 300 shares during the last quarter. Finally, Union Bancaire Privee UBP SA grew its stake in shares of AbbVie by 11.6% during the 4th quarter. Union Bancaire Privee UBP SA now owns 443,006 shares of the company's stock worth $95,348,000 after acquiring an additional 46,028 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.